Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.72 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4469070 | 0.89 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4DRD2DRD1 | |
| SCHEMBL4029581 | 0.88 | SLC6A2 (0.72) | SLC6A2SLC6A3SLC6A4DRD2DRD1 | |
| SCHEMBL4464065 | 0.88 | SLC6A4 (0.65) | SLC6A2SLC6A3SLC6A4DRD2DRD1 | |
| SCHEMBL9193257 | 0.86 | DRD1 (0.67) | DRD2DRD1CYP2D6 | |
| SCHEMBL9193250 | 0.86 | DRD1 (0.67) | DRD2DRD1CYP2D6 | |
| SCHEMBL11639888 | 0.85 | SLC6A2 (0.72) | SLC6A2SLC6A3SLC6A4DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL11640224 | 0.84 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4DRD2DRD1 | |
| SCHEMBL5244519 | 0.84 | SLC6A2 (0.76) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4033945 | 0.84 | DRD1 (0.80) | SLC6A2SLC6A3SLC6A4DRD2DRD1 | |
| SCHEMBL5246721 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911453-B2 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-28 | — | — | US | claimed |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | claimed |
| EP-1453810-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-6911453-B2 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050009864-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1453810-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | Aventis Pharma Deutschland GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
| WO-2003048129-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009864-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | SLC6A2 16/4885SLC6A3 49/4885SLC6A4 45/4885 |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | SLC6A2 18/4885SLC6A3 48/4885SLC6A4 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.